Literature DB >> 27125378

Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Takafumi Nakano1,2, Yoshihiko Nakamura3, Tohru Takata4, Keiichi Irie5, Kazunori Sano5, Osamu Imakyure6, Kenichi Mishima5, Koujiro Futagami6.   

Abstract

Background Target trough concentrations are recommended for teicoplanin (TEIC) to minimize its adverse effects and to maximize efficacy in sepsis caused by grampositive cocci, including methicillin-resistant Staphylococcus aureus infection. However, optimal doses to attain proper trough values in patients with sepsis have not yet been well established for TEIC. Objective This study investigated whether the systemic inflammatory response syndrome (SIRS) score could predict the pharmacokinetics of TEIC in patients with sepsis. Setting This study was conducted at Fukuoka University Hospital in Japan. Methods We retrospectively reviewed the records of patients using TEIC between April 2012 and March 2015. SIRS positive was defined as infection with a SIRS score ≥2. Estimates of pharmacokinetic parameters were calculated using a Bayesian method. Creatinine clearance rates were estimated by the Cockcroft-Gault formula (eCcr). Main outcome measure Change of TEIC loading dose requirement for incremental increases of SIRS score. Results In total, 133 patients were enrolled: 50 non-SIRS patients and 83 patients with SIRS. The TEIC plasma trough concentration was significantly lower in SIRS than non-SIRS patients (15.7 ± 7.1 vs. 20.1 ± 8.6 μg/mL; P < 0.01), although there was no significant difference in the loading dose administered. Moreover, SIRS scores were increasingly predictive of eCcr and TEIC clearance in a stepwise manner. To achieve the target trough concentration (15-30 μg/mL), the optimal doses required in non-SIRS versus SIRS patients were 12-24 versus 18-30 mg/kg/day, respectively, during the first 48 h. Conclusions These findings suggest that the pharmacokinetics of TEIC are altered in SIRS patients, who required higher doses than non-SIRS patients to achieve the target trough concentration. We suggest that the SIRS score can become a new modality to determine the initial TEIC loading dose.

Entities:  

Keywords:  Inflammatory response; Pharmacokinetics; Severe sepsis; Systemic inflammatory response syndrome; Teicoplanin

Mesh:

Substances:

Year:  2016        PMID: 27125378     DOI: 10.1007/s11096-016-0308-3

Source DB:  PubMed          Journal:  Int J Clin Pharm


  36 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome.

Authors:  I Harding; A P MacGowan; L O White; E S Darley; V Reed
Journal:  J Antimicrob Chemother       Date:  2000-06       Impact factor: 5.790

Review 3.  Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK.

Authors:  Curtis G Gemmell; David I Edwards; Adam P Fraise; F Kate Gould; Geoff L Ridgway; Rod E Warren
Journal:  J Antimicrob Chemother       Date:  2006-02-28       Impact factor: 5.790

4.  Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalised patients treated for sepsis.

Authors:  A J Brink; G A Richards; R R Cummins; J Lambson
Journal:  Int J Antimicrob Agents       Date:  2008-08-20       Impact factor: 5.283

5.  Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.

Authors:  Kazuaki Matsumoto; Naoko Kanazawa; Kazuro Ikawa; Tomohide Fukamizu; Akari Shigemi; Keiko Yaji; Yoshihiro Shimodozono; Norifumi Morikawa; Yasuo Takeda; Katsushi Yamada
Journal:  J Infect Chemother       Date:  2010-03-02       Impact factor: 2.211

6.  Renal outcome after vancomycin treatment and renal replacement therapy in patients with severe sepsis and septic shock: a retrospective study.

Authors:  Gordon P Otto; Maik Sossdorf; Hannes Breuel; Peter Schlattmann; Ole Bayer; Ralf A Claus; Niels C Riedemann; Martin Busch
Journal:  J Crit Care       Date:  2014-03-21       Impact factor: 3.425

7.  [Necessity of personalized initial loading dose calculation of teicoplanin by clinical pharmacist-examination of the utility of using systemic inflammatory response syndrome score-].

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Atsushi Togawa; Tohru Takata; Hiroyasu Ishikura; Kenichi Mishima; Koujiro Futagami
Journal:  Yakugaku Zasshi       Date:  2014       Impact factor: 0.302

8.  Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages.

Authors:  Federico Pea; Pierluigi Viale; Anna Candoni; Federica Pavan; Leonardo Pagani; Daniela Damiani; Marco Casini; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Generalized vascular permeability and pulmonary function in patients following serious trauma.

Authors:  P Gosling; K Sanghera; G Dickson
Journal:  J Trauma       Date:  1994-04

10.  Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin.

Authors:  R Minkutė; V Briedis; R Steponavičiūtė; A Vitkauskienė; R Mačiulaitis
Journal:  J Clin Pharm Ther       Date:  2013-08-08       Impact factor: 2.512

View more
  1 in total

Review 1.  Intracellular Pharmacokinetics of Antibacterials and Their Clinical Implications.

Authors:  Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.